Now showing items 1-1 of 1

    • Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma 

      Nakayama, Robert; Zhang, Yi-Xiang; Czaplinski, Jeffrey T.; Anatone, Alex J.; Sicinska, Ewa T.; Fletcher, Jonathan A.; Demetri, George D.; Wagner, Andrew J. (Impact Journals LLC, 2016)
      Selinexor is an orally bioavailable selective inhibitor of nuclear export that has been demonstrated to have preclinical activity in various cancer types and that is currently in Phase I and II clinical trials for advanced ...